GLP-1 and Weight Loss: Understanding, Efficacy, and Challenges

The subject of GLP-1 for weight loss has emerged at the intersection of physiology, nutrition, and the management of overweight and obesity. Part of the interest comes from a simple fact: weight gain is not just a matter of willpower. Biological signals that regulate hunger, satiety, food reward, blood sugar, and the use of energy substrates strongly influence appetite and the ability to maintain a caloric deficit over time.

In this context, GLP-1 (Glucagon-Like Peptide-1) is often presented as the satiety hormone. GLP-1 acts on several axes simultaneously (intestine, pancreas, brain, stomach), and its effects combine with other hormones and neurotransmitters involved in weight regulation. Therefore, GLP-1 and weight loss approaches can be relevant for certain profiles, but they do not replace lifestyle, support, or personalization. The challenge is thus twofold: on one hand, to understand how GLP-1 influences the reduction of cravings, appetite, and food intake, and on the other hand, to know what results are observed, at what rate, for whom it is most effective, and what precautions are necessary.

GLP-1 (Glucagon-Like Peptide-1) is a hormone naturally produced by the intestine, involved in the regulation of blood sugar and appetite. Often referred to as the satiety hormone, it plays a key role in the mechanisms associated with GLP-1 weight loss by influencing hunger, digestion, and satiety signals.

GLP-1 is a peptide produced mainly by specialized cells in the intestine (L cells) in response to the arrival of nutrients after a meal. It belongs to the incretin system, which are intestinal hormones that participate in post-meal metabolic adaptation. GLP-1 has a peculiarity: its circulating half-life is short, as it is rapidly degraded by an enzyme (DPP-4). This explains why, in a GLP-1 weight loss strategy, so-called GLP-1 analogues or GLP-1 agonists are designed to last longer and activate the GLP-1 receptor for an extended period.

Beyond the terminology, retaining the essential helps: GLP-1 is a biological signal that indicates to the body that a meal is in progress or has just occurred. It helps curb the desire to continue eating, improve blood sugar management, and coordinate digestion.

GLP-1 is involved in several complementary mechanisms. Firstly, it enhances insulin secretion in a glucose-dependent manner, meaning the effect is particularly relevant when blood sugar is high after a meal. Secondly, it modulates glucagon secretion (the hormone that promotes glucose release by the liver), contributing to better glycemic stability. Thirdly, it acts on digestive motility, particularly by slowing gastric emptying, which prolongs the feeling of fullness.

Finally, and this is central for weight loss, GLP-1 acts via the gut-brain axis: it sends signals that contribute to satiation (stopping eating) and satiety (the interval between meals). This dimension explains part of the reduction in cravings reported with GLP-1 receptor activation.

The relationship between blood sugar and appetite is bidirectional. Rapid fluctuations in blood sugar can influence hunger in some people, while meals very rich in fast sugars can promote a craving-consumption-craving cycle. GLP-1, by improving glycemic control and slowing gastric emptying, tends to smooth out the post-meal response. This smoothing is not "magical," but it can facilitate the management of internal signals: fewer peaks, fewer troughs, and sometimes a better ability to stop at the right time.

In people with insulin resistance, post-meal regulation can be more difficult, with a tendency to store more and feel hungry faster. In a GLP-1 and weight loss approach, the theoretical interest is therefore twofold: to help better manage the glycemic signal and reduce the intensity of the eating drive. This does not replace diet quality, but it can make changes more sustainable.

The link between GLP-1 and weight loss is based on several biological mechanisms that directly influence appetite, satiety, and digestion. By modulating hunger signals and slowing gastric emptying, GLP-1 naturally helps reduce food intake in a sustainable weight loss strategy.

Talking about weight loss often means talking about hunger control. The activation of the GLP-1 receptor acts as an amplifier of satiation signals: the meal "matters more" in the brain. Concretely, portion sizes can decrease, food thoughts can occupy less mental space, and reducing cravings becomes more accessible for some people.

It is useful to distinguish satiation and satiety. Satiation concerns the moment one stops eating. Satiety concerns the time before hunger returns. GLP-1 can contribute to both: on the one hand, by promoting stopping eating, and on the other hand, by prolonging the feeling of a "full tank" via slower digestion. This combination explains why GLP-1 is described as a satiety hormone, even if the reality involves several hormones (CCK, PYY, leptin, ghrelin, etc.).

Gastric emptying corresponds to the transfer of stomach contents to the intestine. When it is slower, the feeling of fullness lasts longer, and the urge to eat again can be delayed. GLP-1 physiologically contributes to this slowdown, and pharmacological activation of the GLP-1 receptor can accentuate this phenomenon, especially at the beginning.

In practical terms, this also explains some digestive side effects: if the stomach empties more slowly, very large, very fatty, or too quickly consumed meals can become uncomfortable. A GLP-1 and weight loss approach compatible with digestive comfort therefore often favors more modest portions, more attentive chewing, and structured meals, rather than extreme restrictions.

Food intake is not solely dictated by physiological hunger. Stress, fatigue, environment, sleep, taste reward, and habituation play a major role. The interest of GLP-1 and weight loss strategies is also behavioral: by reducing the intensity of the hunger signal and the frequency of intense cravings, they can facilitate choices more consistent with a goal of sustainable weight loss.

However, biology does not replace learning. Even when hunger decreases, certain habits such as automatic snacking, emotional eating, skipped meals followed by evening compensation can persist. A truly sustainable approach therefore combines understanding the hunger signal, meal organization, protein and fiber intake, and management of triggers (stress, lack of sleep). This is often where the difference between transient and sustainable weight loss lies.

GLP-1-based medications are used in certain situations to support weight loss, by acting on the mechanisms of appetite and satiety. They rely on specific molecules, called GLP-1 agonists, which mimic the action of this hormone to promote more effective regulation of food intake.

GLP-1 agonists are molecules that activate the GLP-1 receptor in a prolonged manner. They are designed to mimic the effects of physiological GLP-1, but with an action duration compatible with daily or weekly administration depending on the molecule. This prolonged action is one of the reasons for the efficacy observed in several clinical trials on weight loss.

It is essential to remember that these treatments are medications, with precise indications, dose progression, and medical follow-up. They should not be confused with dietary supplements, and they are not part of an "express program" logic.

Natural GLP-1 has a short half-life. GLP-1 analogues, and more broadly, GLP-1 agonists, are modified to resist degradation, remain in the body longer, and activate the receptor in a sustained manner. This pharmacokinetic difference changes the intensity and duration of effects on appetite, satiety, and gastric emptying.

This also explains an often underestimated reality: the body adapts. The first few weeks may be marked by a clear decrease in appetite, then a plateau, then stabilization. Long-term efficacy then depends on integrating a realistic lifestyle. Clinically, major studies systematically include support (dietary advice, physical activity), which reminds us that weight loss is not an effortless action.

Prescriptions are generally part of overweight and obesity management when eligibility criteria are met (BMI, comorbidities, failure of well-conducted lifestyle approaches, etc.) and when the benefit-risk ratio is deemed favorable. Access recommendations may vary by country and healthcare system; for example, agencies like NICE in the UK regulate the use of semaglutide in structured and multidisciplinary pathways.

In a responsible reading of the subject related to weight loss, it is important to understand that the objective is not to accelerate weight loss. The objective is to improve the weight and metabolic trajectory, in a framework where safety, tolerance, adherence, and the prevention of weight regain are taken into account.

GLP-1 can help reduce appetite. A weight loss strategy using GLP-1 is stronger when based on a structured diet that is sufficiently filling and compatible with social life. The central pillar remains energy balance: a moderate, sustainable calorie deficit that does not rely on the total exclusion of foods. Demonizing food creates frustration, promotes compulsive eating, and increases the risk of weight regain.

Physiologically, meals rich in protein and fiber support satiety. Minimally processed foods, carbohydrates with a moderate glycemic index, and good quality fats contribute to better stability. The goal is not perfection, but the repetition of beneficial choices, most of the time.

Morosil®, a blood orange extract standardized in polyphenols, is sometimes mentioned as support in a weight loss process. Unlike GLP-1 agonists, it does not act directly on appetite or satiety but is part of a metabolic and body composition support logic. It should be considered a complementary lever, integrated into a structured diet and a coherent lifestyle.

Physical activity plays several roles in a GLP-1 and weight loss approach. It helps preserve lean mass during weight loss, improves insulin sensitivity, supports cardiometabolic health, and contributes to long-term maintenance. Here again, the logic is not extreme: regular progression (walking, strength training, mobility) is often more effective than unsustainable peaks of intensity.

An important point concerns fatigue: if appetite decreases sharply, it can be tempting to eat too little, which degrades energy and reduces the desire to move. However, an excessive drop in intake can compromise regularity. A consistent weight loss strategy therefore aims to maintain sufficient food intake to support activity and recovery, while maintaining a reasonable caloric deficit.

The key question is this: is the GLP-1 and weight loss approach a temporary crutch or an aid tool integrated into a global strategy? Trial data shows that efficacy is maximized when accompanied by lifestyle changes.

GLP-1 can reduce biological friction: less hunger, less snacking, more control. But sustainability depends on acquired skills: meal planning, trigger management, improved sleep quality, sufficient movement, hydration. Sleep is often overlooked, yet nocturnal hormonal regulation influences hunger, recovery, and stress management. Similarly, hydration is a simple but structuring variable, especially when digestive side effects exist.

Finally, the approach must remain realistic: an extreme program does not build a trajectory. A sustainable strategy, even a slow one, almost always wins in the long term, particularly by reducing the risk of weight regain.

• STEP 1 trial (semaglutide 2.4 mg) - NEJM, "Once-Weekly Semaglutide in Adults with Overweight or Obesity".
• Liraglutide 3.0 mg trial - NEJM, "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management".
• SURMOUNT-1 trial (tirzepatide) - NEJM, "Tirzepatide Once Weekly for the Treatment of Obesity".
• Review of GLP-1 mechanisms (appetite, satiety, gastric emptying) - Trends in Endocrinology & Metabolism.
• Review of gut-brain and food intake control - "Intestinal GLP-1 effects on food intake…"